Intraperitoneal, mouse LD10 = 500 mg/kg. Intravenous, dog LD10 = 2 gm/kg.
An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. PubChem
The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Dexrazoxane. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Dexrazoxane. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dexrazoxane. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dexrazoxane. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Dexrazoxane. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dexrazoxane. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Dexrazoxane. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Dexrazoxane. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Dexrazoxane. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexrazoxane. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Dexrazoxane. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexrazoxane. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dexrazoxane. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Dexrazoxane. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dexrazoxane. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dexrazoxane. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Dexrazoxane. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexrazoxane. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Dexrazoxane. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexrazoxane. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexrazoxane. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexrazoxane. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Dexrazoxane. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexrazoxane. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexrazoxane. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dexrazoxane. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexrazoxane. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dexrazoxane. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Dexrazoxane. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Dexrazoxane. |
| Cladribine | Dexrazoxane may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Dexrazoxane. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Dexrazoxane. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Dexrazoxane. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Dexrazoxane. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dexrazoxane. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Dexrazoxane. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Dexrazoxane. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Dexrazoxane. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Dexrazoxane. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Dexrazoxane. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Dexrazoxane. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Dexrazoxane. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Beclomethasone dipropionate. |
| Sorafenib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sorafenib. |
| Streptozocin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Streptozocin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trifluridine. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Gemcitabine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Betamethasone. |
| Teniposide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Teniposide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Epirubicin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Chloramphenicol. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Lenalidomide. |
| Altretamine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Altretamine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Zidovudine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Oxaliplatin. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cyclophosphamide. |
| Vincristine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vincristine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pentostatin. |
| Methotrexate | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Methotrexate. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Carbamazepine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vinblastine. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocinolone acetonide. |
| Linezolid | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Linezolid. |
| Imatinib | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Imatinib. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Triamcinolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Clofarabine. |
| Prednisone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Prednisone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pemetrexed. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fludrocortisone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mycophenolate mofetil. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Daunorubicin. |
| Irinotecan | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Irinotecan. |
| Methimazole | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Methimazole. |
| Etoposide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Etoposide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dacarbazine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Temozolomide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Penicillamine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Prednisolone. |
| Sirolimus | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sirolimus. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Azacitidine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Carboplatin. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Methylprednisolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dactinomycin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cytarabine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Azathioprine. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydroxyurea. |
| Busulfan | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Busulfan. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Melphalan. |
| Fludarabine | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fludarabine. |